Trista Marie Benitez1, Shannon Melania Fernando1, Christina Amini1, Sammy Saab2,3. 1. Los Angeles Christian Health Centers, Los Angeles, CA, USA. 2. Departments of Medicine, Nursing, and Surgery, University of California at Los Angeles, Los Angeles, CA, USA. SSaab@mednet.ucla.edu. 3. Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA, 90095, USA. SSaab@mednet.ucla.edu.
Abstract
BACKGROUND: The inequitable prevalence of hepatitis C (HCV) in the homeless is a clinical and public health concern. Prior research estimates, at least one-quarter of homeless persons have been infected with HCV, yet linkage to care and treatment uptake remains marginal. AIM: To evaluate the feasibility of treating HCV in a homeless population. METHODS: Retrospective study of homeless individuals treated for HCV. Demographic information including risk factors was collected. Univariate analyses were performed. The proportion of patients linked to care and sustained viral response at 12 weeks post-treatment (SVR12) was measured. RESULTS: During the study period, 6767 individuals were screened for HCV. A total of 769 (11.4%) were found to have detectable HCV antibodies. Of the individuals with detectable HCV antibodies, 443 (57.6%) were viremic. Of the 443 viremic patients, 375 (84.7%) were linked to care. Among them, 59 patients began antiviral treatment and 95% (56/59) completed the course of therapy. The ITT was 83.1% (49/59), and the per-protocol virologic cure rate was 100% (49/49). CONCLUSION: The favorable linkage to care and cure outcomes in our study suggests that homeless persons may be more likely to engage in HCV screening and treatment when these services are located in the community for their use. Our study further lends support to the efficacy of care coordination programs to encourage movement through the HCV care continuum in vulnerable populations.
BACKGROUND: The inequitable prevalence of hepatitis C (HCV) in the homeless is a clinical and public health concern. Prior research estimates, at least one-quarter of homeless persons have been infected with HCV, yet linkage to care and treatment uptake remains marginal. AIM: To evaluate the feasibility of treating HCV in a homeless population. METHODS: Retrospective study of homeless individuals treated for HCV. Demographic information including risk factors was collected. Univariate analyses were performed. The proportion of patients linked to care and sustained viral response at 12 weeks post-treatment (SVR12) was measured. RESULTS: During the study period, 6767 individuals were screened for HCV. A total of 769 (11.4%) were found to have detectable HCV antibodies. Of the individuals with detectable HCV antibodies, 443 (57.6%) were viremic. Of the 443 viremic patients, 375 (84.7%) were linked to care. Among them, 59 patients began antiviral treatment and 95% (56/59) completed the course of therapy. The ITT was 83.1% (49/59), and the per-protocol virologic cure rate was 100% (49/49). CONCLUSION: The favorable linkage to care and cure outcomes in our study suggests that homeless persons may be more likely to engage in HCV screening and treatment when these services are located in the community for their use. Our study further lends support to the efficacy of care coordination programs to encourage movement through the HCV care continuum in vulnerable populations.
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Daan W Von den Hoff; Floor A C Berden; Femke Atsma; Arnt F A Schellekens; Joost P H Drenth Journal: J Clin Med Date: 2022-02-21 Impact factor: 4.241
Authors: Diana Partida; Jesse Powell; Margaret Ricco; Jessica Naugle; Catherine Magee; Barry Zevin; Carmen L Masson; J Konadu Fokuo; Daniel Gonzalez; Mandana Khalili Journal: Open Forum Infect Dis Date: 2022-03-01 Impact factor: 3.835
Authors: Ria Saha; Amanda P Miller; Andrea Parriott; Hacsi Horvath; James G Kahn; Mohsen Malekinejad Journal: BMC Public Health Date: 2022-07-26 Impact factor: 4.135
Authors: A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis Journal: Int J Drug Policy Date: 2021-07-27